Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.
about
Markedly Elevated Antibody Responses in Wild versus Captive Spotted Hyenas Show that Environmental and Ecological Factors Are Important Modulators of ImmunitySingle-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteersPharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infectionPlasma drug activity in patients on treatment for multidrug-resistant tuberculosisPlasma drug activity assay for treatment optimization in tuberculosis patients.Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.BRL-36650: in vitro studies and assessment of serum bactericidal activity after single-dose administration in volunteers.Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin.Protein binding and serum bactericidal activities of vancomycin and teicoplanin.Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.Crossover assessment of serum bactericidal activity and pharmacokinetics of five broad-spectrum cephalosporins in the elderly.Effects of supraphysiologic temperature and broth dilution on serum protein binding.Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplaninPharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteersConcentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orallyEx vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycinComparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimensComparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers.Susceptibility of enterococci to trimethoprim and trimethoprim-sulfamethoxazoleAssessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects.Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin.Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa.Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections.Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolideMinimum inhibitory and bactericidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serumComparative in vitro activities of temocillin and cefazolin against Klebsiella pneumoniae.Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampinComparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime.4-week treatment of streptococcal native valve endocarditis with high-dose teicoplaninBactericidal titers of loracarbef (LY 163892) in serum and killing rates in volunteers receiving 400 versus 200 milligrams.Serum bactericidal testRandomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.Effect of abnormal levels of serum components on antibiotic activity.Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.Effect of ertapenem protein binding on killing of bacteria.Osteomyelitis of the long bones.
P2860
Q21124201-96B98ABF-78A9-4586-B3E9-A29ACFDEE066Q24679375-32BA4122-18D2-4FC1-A55E-6725DA7BAE83Q28328534-F032651C-56D7-478E-B90A-BCD6666F017DQ30411475-969BF860-F6AB-4842-9998-F1E17C27D299Q30426583-04CACEF8-D118-4D31-A3B7-0A2F22351B09Q30451758-DF1B83B7-2E42-438C-AB82-9B80BC9B25E0Q33738474-27C8F627-0AF3-4E8C-A353-6A510690069DQ33740774-4FB91E07-5620-4457-9EB8-7B54A84C5BC3Q35117545-6DF40159-0EE5-4D52-A482-AAD2FCC5290FQ35121441-78DF1CC6-AF43-4D97-A23C-54A9D47C1AF8Q35123325-A9FE7CB0-48DC-45F4-9347-86FFDADF6203Q35258426-021CFBF5-EC8C-4247-9A10-93065057D79AQ35263450-D5E1BC90-6E16-434F-8E88-5E6B625A8C5FQ35285763-EC6B89A7-138D-4F81-960E-186FD9282CFAQ35285981-49561827-BA18-4802-A1BA-B2BA705645BEQ35289147-17B452D3-4ABA-4655-B464-80062BFDB0E2Q35353895-B72FF4E6-4584-4B45-AA33-F78461D32497Q35355587-33761FCC-7489-4289-9884-CE82A9BADA44Q35565851-1CFE38F6-B0F7-4B8D-B74E-3CA918087A35Q35568394-717654CA-913F-4E31-9023-A924EF3FCD42Q35568914-34D3D081-E5C2-4EFC-84B4-C324A53989C8Q35571379-8358D25E-1D7E-4185-8051-2B74645E8918Q35573196-DC6F0E66-35F0-4784-858B-5CD32228391FQ35574386-8AD426D9-F010-4340-A34B-84EC45B28212Q35647232-19677FF6-83DB-4BF1-B088-AD279A36470CQ35648690-9EF07B48-B984-472F-83E3-BD61E9FDFC84Q35653665-C47DEB01-A0A5-447A-B000-33899210F59EQ35670703-6927648D-C78D-4544-9133-CFA683AEF905Q35715359-A07B94CC-F4AB-4FED-BB94-0814EFCB9533Q35745822-1C389A4B-6485-41F3-9245-EBD2ECB7D31CQ35819020-5D107D55-A049-420F-BCF7-03C805BA7197Q35819061-78D8E568-82E1-4513-8A1D-0CB839486685Q35845550-08F60D00-92D7-432E-A90D-68B99079350EQ35866980-31DF19E8-E95B-49D1-B4F5-3C11715E1452Q36632471-FAD7AE49-96C5-4AFD-B44B-ED80208CCA41Q36753066-0A369B17-374F-4F01-81A2-829CF44B5954Q36753468-8CE0A905-FE38-4A6A-BB7C-2BDA8237931FQ36757684-87CB64B0-A16F-41C2-8CBE-E7AC022850E6Q37488804-E0E44E61-3D1A-4DDF-A1EC-D43698B57AC4Q37766771-C054504E-F8A8-489D-9C8D-36382882D8A9
P2860
Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年学术文章
@wuu
1977年学术文章
@zh-cn
1977年学术文章
@zh-hans
1977年学术文章
@zh-my
1977年学术文章
@zh-sg
1977年學術文章
@yue
1977年學術文章
@zh
1977年學術文章
@zh-hant
name
Serum dilution test for bacter ...... says and susceptibility tests.
@en
type
label
Serum dilution test for bacter ...... says and susceptibility tests.
@en
prefLabel
Serum dilution test for bacter ...... says and susceptibility tests.
@en
P356
P1476
Serum dilution test for bacter ...... says and susceptibility tests.
@en
P2093
Stratton CW
P304
P356
10.1093/INFDIS/136.2.196
P407
P577
1977-08-01T00:00:00Z